Qube Research & Technologies (QRT)’s Ultragenyx Pharmaceutical RARE Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.5M	Sell	882,219 -32,541	-4%	-$808K	0.03%	721
2026 Q1	$19.2M	Buy	+914,760	New	+$20.6M	0.02%	903
2024 Q2	–	Sell	-642	Closed	-$30K	–	4554
2024 Q1	$30K	Buy	+642	New	+$30.3K	﹤0.01%	3615
2022 Q4	–	Sell	-30,774	Closed	-$1.27M	–	2897
2022 Q3	$1.27M	Buy	+30,774	New	+$1.58M	0.01%	1105
2021 Q3	–	Sell	-30,246	Closed	-$2.88M	–	2677
2021 Q2	$2.88M	Buy	30,246 +25,550	+544%	+$2.66M	0.03%	581
2021 Q1	$535K	Sell	4,696 -11,876	-72%	-$1.62M	0.01%	1139
2020 Q4	$2.29M	Buy	+16,572	New	+$1.97M	0.03%	566

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Qube Research & Technologies (QRT)'s RARE Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Ultragenyx Pharmaceutical (RARE) stake by 3.6% in Q2 2026, selling an estimated $808K and leaving 882,219 shares worth $29.5M. The position accounts for 0.03% of the portfolio, ranked #721.

Qube Research & Technologies (QRT) first reported a position in RARE in Q4 2020 and has held it in 7 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Qube Research & Technologies (QRT) held 882,219 shares of Ultragenyx Pharmaceutical worth $29.5M as of Q2 2026.
Qube Research & Technologies (QRT) sold 32,541 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $808K.
Ultragenyx Pharmaceutical made up 0.03% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #721 holding.
Qube Research & Technologies (QRT) first reported a position in Ultragenyx Pharmaceutical in Q4 2020 and has held it in 7 quarters since.
311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.